Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 24,903 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the transaction, the chief financial officer now owns 62,821 shares in the company, valued at approximately $3,689,477.33. This trade represents a 28.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Protagonist Therapeutics Stock Performance
Protagonist Therapeutics stock traded up $1.51 during midday trading on Tuesday, reaching $54.52. The stock had a trading volume of 784,643 shares, compared to its average volume of 739,598. The firm's fifty day simple moving average is $39.93 and its 200-day simple moving average is $42.31. Protagonist Therapeutics, Inc. has a 1-year low of $24.22 and a 1-year high of $60.60. The stock has a market capitalization of $3.35 billion, a P/E ratio of 20.50 and a beta of 2.34.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $2.07. The firm had revenue of $170.64 million for the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. On average, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. FNY Investment Advisers LLC acquired a new position in shares of Protagonist Therapeutics during the 4th quarter worth approximately $38,000. GF Fund Management CO. LTD. bought a new position in shares of Protagonist Therapeutics during the 4th quarter worth approximately $48,000. Harvest Fund Management Co. Ltd bought a new position in shares of Protagonist Therapeutics during the 3rd quarter worth approximately $69,000. Covestor Ltd boosted its stake in shares of Protagonist Therapeutics by 5,200.0% during the 4th quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after acquiring an additional 1,612 shares during the period. Finally, KBC Group NV boosted its stake in shares of Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after acquiring an additional 737 shares during the period. Institutional investors and hedge funds own 98.63% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. BTIG Research set a $73.00 price target on Protagonist Therapeutics in a research report on Monday, March 3rd. StockNews.com lowered Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. HC Wainwright reaffirmed a "buy" rating and set a $54.00 price target on shares of Protagonist Therapeutics in a research report on Monday, March 10th. Wedbush reaffirmed an "outperform" rating and set a $70.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, March 11th. Finally, The Goldman Sachs Group dropped their price target on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $62.56.
View Our Latest Research Report on Protagonist Therapeutics
About Protagonist Therapeutics
(
Get Free Report)
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Further Reading
Before you consider Protagonist Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.
While Protagonist Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
